mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

Published:2017-02-02 Issue:7 Volume:37 Page:1047-1055
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Meyer Tim¹,Palmer Daniel H.²³,Cheng Ann-Lii⁴,Hocke Julia⁵,Loembé Arsène-Bienvenu⁶,Yen Chia-Jui⁷

Affiliation:

1. UCL Cancer Institute; University College London; London UK

2. Department of Molecular and Clinical Cancer Medicine; University of Liverpool; Liverpool UK

3. Clatterbridge Cancer Centre; Bebington UK

4. National Taiwan University Hospital; Taipei Taiwan

5. Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach Germany

6. Boehringer Ingelheim B.V.; Alkmaar the Netherlands

7. National Cheng Kung University Hospital; Tainan Taiwan

Funder

Boehringer Ingelheim

Bayer

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13359/fullpdf

Reference22 articles.

1. Design and endpoints of clinical trials in hepatocellular carcinoma;Llovet;J Natl Cancer Inst,2008

2. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada;Therasse;J Natl Cancer Inst,2000

3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

4. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

5. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study;Llovet;J Clin Oncol,2013

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters;Abdominal Radiology;2024-03-28

2. Evolution of Liver Transplantation Indications: Expanding Horizons;Medicina;2024-02-28

3. Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma;Liver Cancer;2023-11-29

4. Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy;Hepatology Communications;2023-09-15

5. Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3